Tone mix
Week by week 51 weeks
Share of Agenus Inc.'s 139 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of May 11, 2026 · tone -100Agenus (NASDAQ:AGEN) Releases Earnings Results, Misses Expectations By $1.08 EPS-168
- Week of Dec 22, 2025 · tone +91Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC+117
- Week of Dec 9, 2024 · tone +99Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus+112
- Week of Jul 20, 2026 · tone -46Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing-106
- Week of Sep 1, 2025 · tone +100Agenus' (AGEN) Buy Rating Reiterated at HC Wainwright+83
- Week of Oct 13, 2025 · tone 0Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights-80
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Agenus Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 1 | +85 |
| Last 30 sessions | 9 | +43 |
| Last 90 sessions | 35 | +45 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
1 headline, average tone +85: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.finanznachrichten.de · 1 outletAgenus Inc.: Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Agenus Inc.: Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletImageneBio (NASDAQ:IMA) versus Agenus (NASDAQ:AGEN) Financial SurveyNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| ImageneBio (NASDAQ:IMA) versus Agenus (NASDAQ:AGEN) Financial Survey | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 8, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.elliotlakestandard.ca · 3 outletsArmenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal CancerPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer | www.elliotlakestandard.ca | 3 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 6, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletAgenus' (AGEN) Buy Rating Reaffirmed at Chardan CapitalPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Agenus' (AGEN) Buy Rating Reaffirmed at Chardan Capital | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 5, 2026
1 headline, average tone +99: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.northernnews.ca · 16 outletsAgenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 | www.northernnews.ca | 16 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Agenus Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.